Physician profile
Charan Singh
NPI 1821046319
$3,163.47
in general payments reported to CMS, 2019-2025
32 companies · $257 in 2025
The $257 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $472 · 2020: $760 · 2021: $400 · 2022: $669 · 2023: $333 · 2024: $273 · 2025: $257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $813 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $813.16 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $376.16 | 2020-2022 | |
| Livanova USA, INC. | $360.96 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Abbvie INC. | $305.64 | 2021-2025 | Botox, Vraylar |
| Alexion Pharmaceuticals, INC. | $176.34 | 2020-2025 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $149.45 | 2019-2022 | |
| Amgen INC. | $148.09 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $146.01 | 2021 | |
| Sunovion Pharmaceuticals INC. | $134.28 | 2020-2022 | |
| Polynovo North America LLC | $131.33 | 2024-2025 | Novosorb Btm |
| Biogen, INC. | $116.30 | 2021-2025 | Vumerity, Plegridy, Avonex |
| Ucb, INC. | $110.07 | 2022-2025 | Briviact, Zilbrysq |
| Boston Scientific Corporation | $108.73 | 2020 | |
| Avanir Pharmaceuticals, INC. | $100.18 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $75.78 | 2022-2024 | Xarelto |
| Sk Life Science, INC. | $70.95 | 2020-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $66.94 | 2022-2025 | Ocrevus Zunovo |
| Genzyme Corporation | $66.43 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $66.41 | 2022 | |
| Pfizer INC. | $65.08 | 2023-2024 | |
| Adamas Pharmaceuticals, INC. | $51.42 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $50.68 | 2023-2025 | Rexulti |
| Lilly USA, LLC | $46.91 | 2019-2020 | |
| Acorda Therapeutics, INC | $44.93 | 2022-2023 | Inbrija, Ampyra |
| Novartis Pharmaceuticals Corporation | $44.46 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $27.86 | 2024 | Lynparza, Keytruda |
| Upsher-Smith Laboratories LLC | $20.71 | 2020 | |
| Banner Life Sciences, LLC | $20.60 | 2022 | |
| Supernus Pharmaceuticals, INC. | $19.34 | 2022 | |
| Impel Pharmaceuticals INC. | $18.96 | 2023 | Trudhesa |
| Vertical Pharmaceuticals, LLC | $15.64 | 2019 | |
| Aquestive Therapeutics, INC. | $15.35 | 2020 | |
| Sanofi-Aventis U.S. LLC | $11.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charan Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.